In utero CRISPR-mediated therapeutic editing of metabolic genes
暂无分享,去创建一个
Li Li | Kiran Musunuru | Rajan Jain | E. Morrisey | Rajan Jain | K. Musunuru | P. Zoltick | Kshitiz Singh | H. A. Hartman | Li Li | W. Peranteau | Edward E Morrisey | Avery C Rossidis | John D Stratigis | Alexandra C Chadwick | Heather A Hartman | Nicholas J Ahn | Haiying Li | Kshitiz Singh | Barbara E Coons | Wenjian Lv | Philip W Zoltick | Deepthi Alapati | William Zacharias | William H Peranteau | Heather A. Hartman | Wenjian Lv | Haiying Li | W. Zacharias | A. Rossidis | A. Chadwick | D. Alapati | J. Stratigis | W. Zacharias | Barbara E. Coons | Nicholas J. Ahn | Li Li | Kshitiz Singh | John Stratigis
[1] W. Harrington,et al. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. , 2018, Cell reports.
[2] T. Walters,et al. Co-delivery of a laminin-111 supplemented hyaluronic acid based hydrogel with minced muscle graft in the treatment of volumetric muscle loss injury , 2018, PloS one.
[3] Daniel G. Anderson,et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing , 2017, Nature Biotechnology.
[4] Kiran Musunuru,et al. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing , 2017, Arteriosclerosis, thrombosis, and vascular biology.
[5] Daesik Kim,et al. Genome-wide target specificities of CRISPR RNA-guided programmable deaminases , 2017, Nature Biotechnology.
[6] David A. Brafman,et al. The Impact of Chromatin Dynamics on Cas9-Mediated Genome Editing in Human Cells. , 2017, ACS synthetic biology.
[7] E. Olson,et al. Notch Inhibition Enhances Cardiac Reprogramming by Increasing MEF2C Transcriptional Activity , 2017, Stem cell reports.
[8] Kevin T. Zhao,et al. Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions , 2017, Nature Biotechnology.
[9] A. Flake,et al. Induction of Immune Tolerance to Foreign Protein via Adeno-Associated Viral Vector Gene Transfer in Mid-Gestation Fetal Sheep , 2017, PloS one.
[10] Pavel Sumazin,et al. Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia , 2016, Nature Communications.
[11] J. Joly,et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR , 2016, Genome Biology.
[12] A. Flake,et al. The Intravenous Route of Injection Optimizes Engraftment and Survival in the Murine Model of In Utero Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[13] David R. Liu,et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage , 2016, Nature.
[14] S. Ghaffari,et al. Prenatal Diagnosis of Tyrosinemia Type 1 Using Next Generation Sequencing , 2016, Fetal and pediatric pathology.
[15] Kiran Musunuru,et al. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo—Brief Report , 2016, Arteriosclerosis, thrombosis, and vascular biology.
[16] Yang Yang,et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice , 2016, Nature Biotechnology.
[17] Daniel G. Anderson,et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo , 2016, Nature Biotechnology.
[18] Zhiping Weng,et al. Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. , 2015, Human gene therapy.
[19] David A. Scott,et al. In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.
[20] Daniel J. Rader,et al. Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing , 2014, Circulation research.
[21] Hao Yin,et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.
[22] W. Pu,et al. Peritruncal Coronary Endothelial Cells Contribute to Proximal Coronary Artery Stems and Their Aortic Orifices in the Mouse Heart , 2013, PloS one.
[23] Felipe Ortega,et al. Oligodendrogliogenic and neurogenic adult subependymal zone neural stem cells constitute distinct lineages and exhibit differential responsiveness to Wnt signalling , 2013, Nature Cell Biology.
[24] J. Epstein,et al. Hopx expression defines a subset of multipotent hair follicle stem cells and a progenitor population primed to give rise to K6+ niche cells , 2013, Development.
[25] S. Mittal,et al. Adenoviral vector immunity: its implications and circumvention strategies. , 2011, Current gene therapy.
[26] M. Kay,et al. Adeno‐associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo , 2010, Hepatology.
[27] K. High,et al. Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[28] Thomas Ferkol,et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. , 2007, Human gene therapy.
[29] Aarati R. Ranade,et al. Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice , 2007, Nature Biotechnology.
[30] Marcela V Maus,et al. CD8+ T-cell responses to adeno-associated virus capsid in humans , 2007, Nature Medicine.
[31] Jonathan C. Cohen,et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.
[32] M. Dallman,et al. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. , 2003, Blood.
[33] L. Hauser,et al. Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[34] G. Lipshutz,et al. Reexpression following readministration of an adenoviral vector in adult mice after initial in utero adenoviral administration. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[35] G. Morrow,et al. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1. , 2017, Advances in experimental medicine and biology.
[36] P. Zoltick,et al. The developmental stage determines the distribution and duration of gene expression after early intra-amniotic gene transfer using lentiviral vectors , 2010, Gene Therapy.